Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases
Acta Pharmaceutica Sinica B · 2023-02 · 13 (2) · 678-693
DOI: 10.1016/j.apsb.2022.09.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2023-02. Verfasst von Haowen Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China. Die Arbeit wurde bisher 102-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
The NLRP3 inflammasome's core and most specific protein, NLRP3, has a variety of functions in inflammation-driven diseases. Costunolide (COS) is the major active ingredient of the traditional Chinese medicinal herb Saussurea lappa and has anti-inflammatory activity, but the principal mechanism and molecular target of COS remain unclear. Here, we show that COS covalently binds to cysteine 598 in NACHT domain of NLRP3, altering the ATPase activity and assembly of NLRP3 inflammasome. We declare COS's great anti-inflammasome efficacy in macrophages and disease models of gouty arthritis and ulcerative colitis via inhibiting NLRP3 inflammasome activation. We also reveal that the α-methylene-γ-butyrolactone motif in sesquiterpene lactone is the certain active group in inhibiting NLRP3 activation. Taken together, NLRP3 is identified as a direct target of COS for its anti-inflammasome activity. COS, especially the α-methylene-γ-butyrolactone motif in COS structure, might be used to design and produce novel NLRP3 inhibitors as a lead compound.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
- School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou 311399, China.
- Medical Research Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Xu, H., Chen, J., Chen, P., Li, W., Shao, J., Hong, S., Wang, Y., Chen, L., Luo, W., & Liang, G. (2023). Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases. Acta Pharmaceutica Sinica B, 13(2), 678-693. https://doi.org/10.1016/j.apsb.2022.09.014
Vancouver
Xu H, Chen J, Chen P, Li W, Shao J, Hong S, et al. Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases. Acta Pharmaceutica Sinica B. 2023;13(2):678-693. doi:10.1016/j.apsb.2022.09.014
BibTeX
@article{Xu2023,
author = {Xu, Haowen and Chen, Jiahao and Chen, Pan and Li, Weifeng and Shao, Jingjing and Hong, Shanshan and Wang, Yi and Chen, Lingfeng and Luo, Wu and Liang, Guang},
title = {Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases},
journal = {Acta Pharmaceutica Sinica B},
year = {2023},
volume = {13},
number = {2},
pages = {678--693},
doi = {10.1016/j.apsb.2022.09.014}
}
EUVIMED